The ingredient significantly lowered both circulating glucose and insulin levels after subjects consumed 70 g of sucrose.
Pharmachem Laboratories’ (Kearny, NJ) Phase 3 Sugar Controller ingredient has been shown in two studies, published as one study in Nutrition Journal, to significantly lower both circulating glucose and insulin levels after consumption of a 70 g of sucrose.
Study one was conducted in two phases. In the first phase, 20 subjects were given 70 g of sucrose. They then completed capillary glucose measurements at 30, 45, 60, and 90 minutes, for control measurements. The next day, subjects again took 7 g of sucrose, but also consumed Phase 3 Sugar Controller, which is a novel formula of L-arabinose and a trivalent, patented food-source of chromium.
In the second phase of study one, 10 subjects took Phase 3 Sugar Controller and the sucrose for a longer period of time, for four weeks, followed by baseline capillary tests at the end of each of the four weeks.
In the second study, the same procedures used in the first phase were repeated with 50 subjects, plus the addition of circulating insulin measurements at 30 and 60 minutes from baseline.
“The data from these two separate studies reveal that a formula containing Phase 3 Sugar Controller can facilitate a consistent suppression of both circulating glucose and insulin, without adverse side effects,” wrote lead researcher Gilbert R. Kaats, PhD.
“The replication of the suppressive effect observed in the two sequential studies increases the confidence of the formula’s efficacy,” he added.
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.